Navigation Links
960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter
Date:3/18/2008

Study Successfully Hit Primary End Point of Preventing Bacterial

Colonization with a Trend Toward Superiority over the Market Leader

VANCOUVER, March 18 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced today that the clinical data from its 960 patient clinical trial comparing its 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) with a chlorhexidine/silver sulfadiazine (CH-SS) coated CVC was presented by the clinical investigators at the 28th International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium. Angiotech believes this study is the largest head-to-head coated CVC clinical trial ever completed.

Based on the clinical trial data, the investigators concluded that Angiotech's 5-FU CVC met the primary endpoint of the study: non-inferior in its ability to prevent bacterial colonization of the catheter tip when compared to catheters coated with CH-SS. The rate of colonization of the 5-FU CVC was 2.9% (n=12), compared to 5.3% (n=21) in the CH-SS coated catheters (relative reduction in colonization with 5-FU coating of 46%, p=0.055).

There were no statistically significant differences in the rate of adverse events related to the study devices (2.5% for 5-FU vs. 3.1% for CH-SS), or in the rates of catheter-related bloodstream infections (CRBSI), (0% for 5-FU vs. 2.8% for CH-SS). Additionally, there was no evidence for acquired resistance to 5-FU in clinical isolates exposed to the drug for a second time.

-------------------------------------------------------------------------

Outcome 5-FU CVC CH-SS CVC Endpoint met?'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Industries’ (BI) advanced cell culture products, announces the availability of BI’s line of ... by Biological Industries, these stem cell differentiation media offer a complete system for ...
(Date:7/28/2015)... 2015 A n ... rapidly developing and commercialising innovative medicines to transform patient ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical ... £76.5m), gross, from blue chip institutional investors and simultaneously ...
(Date:7/28/2015)... 28, 2015  PDL BioPharma, Inc. (PDL, or the ... Company will release its second quarter 2015 financial results ... August 5, 2015, after market close. PDL,s management will ... 4:30 p.m. Eastern Time to discuss the financial results. ... available via the webcast link on the PDL website. ...
(Date:7/28/2015)... ... July 28, 2015 , ... In terms of value, aluminium ... production volume reached close to 1.84 million tonnes in the same year. As ... of the region’s total aluminium hydroxide production; the country’s aluminium hydroxide production posted ...
Breaking Biology Technology:Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3
... ... reliable and effective hospital-grade disinfectants against H1N1 and Influenza A., , ... Spartanburg, SC (PRWEB) November 24, 2009 ... that their Sporicidin disinfectants have been deemed by the EPA as effective ...
... , ... Sullivan, the Growth Partnership Company, honored healthcare companies for ... the Excellence in Healthcare Innovation Awards Banquet held in ... , The Healthcare Innovation Awards are given to companies ...
... , , , , , , ... AUDIO: A team of scientists from Washington University in St. Louis, the University of Arizona, Cold Spring Harbor Laboratory and Iowa State ... information. , , , , ... , , , , , , , ...
Cached Biology Technology:Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... of Americans are obese, and these individuals often experience ... cardiovascular problems. In response to the so-called "obesity epidemic," ... health outcomes of obese individuals through diet and exercise. ... certain exercises that benefit obese men may not have ...
... Institute for Biological Studies has received a $42 million ... Center for Genomic Medicine (HCGM), a research center dedicated ... chronic human diseases. The award, from the Leona ... interdisciplinary research that paves the way to new therapies ...
... SAN DIEGO , Jan. 23, 2013 ... discovery and development of innovative treatments for cardiovascular ... and Trademark Office (USPTO) issued a notice of ... claims that cover methods for identifying compounds that ...
Cached Biology News:Women must do more to reap same positive health outcomes as men, MU research suggests 2Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust 2Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust 3Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office 2Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office 3
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... is integrated informatics solution for the ... drug response modeling. This web-based software ... knowledge base of biological networks, and ... capable of extracting pathway-related information from ...
Biology Products: